<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677855</url>
  </required_header>
  <id_info>
    <org_study_id>PCUR101-003</org_study_id>
    <nct_id>NCT04677855</nct_id>
  </id_info>
  <brief_title>Study of PCUR-101 in Combination With ADT in Patients With mCRPC</brief_title>
  <official_title>A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pellficure Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pellficure Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, non-randomized, Phase I, dose escalation/dose expansion study in&#xD;
      cohorts of patients with metastatic CRPC at Screening. Dose escalation uses a 3+3 design to&#xD;
      determine the maximum tolerated dose (MTD). Once the MTD is defined, the dose expansion phase&#xD;
      is used to define the recommended phase 2 dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose Escalation Phase: Eligible patients will enter the study and start receiving daily doses&#xD;
      of PCUR-101 during Cycle 1. Subsequent dose cohorts will receive the next higher dose of&#xD;
      PCUR-101 according to a 3 + 3 design until the MTD is determined. Patients may remain on&#xD;
      these treatment cycles if they do not progress or experience any dose limiting toxicities&#xD;
      (DLTs).&#xD;
&#xD;
      Dose Expansion Phase: Once the MTD has been determined, approximately 18 patients in 3&#xD;
      cohorts will be enrolled for further evaluations of safety, PK, and preliminary clinical&#xD;
      activity during successive 28-day cycles in the dose expansion phase: Expansion Cohort 1 will&#xD;
      receive PCUR-101 at the MTD, Expansion Cohort 2 will receive PCUR-101 at one dose level lower&#xD;
      than the MTD and dutasteride once daily, and Expansion Cohort 3 (6 patients) will receive&#xD;
      PCUR-101 at one dose level lower than the MTD in patients about to start abiraterone (1000 mg&#xD;
      QD) and prednisone (5 mg twice daily [BID]) as their standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 dose escalation followed by a dose expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicity</measure>
    <time_frame>over the first 28 days of dosing</time_frame>
    <description>Incidence of Adverse Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters - Tmax</measure>
    <time_frame>over the first 28 days of dosing</time_frame>
    <description>time to peak concentrations of PCUR-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters - Cmax</measure>
    <time_frame>over the first 28 days of dosing</time_frame>
    <description>peak concentrations of PCUR-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters - T1/2</measure>
    <time_frame>over the first 28 days of dosing</time_frame>
    <description>time from maximum concentration PCUR-101 to a reduction of plasma concentration by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Evidence of efficacy/anti tumor activity - PSA levels</measure>
    <time_frame>through study completion, average of 12 months</time_frame>
    <description>as assessed by PSA changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Evidence of efficacy/anti tumor activity - RECIST</measure>
    <time_frame>through study completion, average of 12 months</time_frame>
    <description>as assessed by RECIST 1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PCUR-101 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCUR-101 dosed orally once per day in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCUR-101</intervention_name>
    <description>50 mg capsules</description>
    <arm_group_label>PCUR-101 Dose Escalation</arm_group_label>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 2</arm_group_label>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride 0.5 mg</intervention_name>
    <description>0.5 mg capsules</description>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone and Prednisone</intervention_name>
    <description>500 mg tablets Abiraterone with 5 mg Prednisone Tablets</description>
    <arm_group_label>PCUR-101 Dose Expansion Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of prostate cancer&#xD;
&#xD;
          -  Demonstrates metastatic CRPC&#xD;
&#xD;
          -  Castrate level of serum testosterone at screening&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic function&#xD;
&#xD;
          -  ECOG status â‰¤1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  No more than one prior course of cytotoxic chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer&#xD;
             histology&#xD;
&#xD;
          -  Visceral metastasis excluding lymph nodes&#xD;
&#xD;
          -  Use of opiate analgesics for prostate cancer pain or non-cancer pain&#xD;
&#xD;
          -  other investigational agents or concurrent anticancer therapy other than standard&#xD;
             androgen deprivation therapy within 4 weeks&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  Concomitant use of warfarin&#xD;
&#xD;
          -  Prior exposure to PCUR-101&#xD;
&#xD;
          -  History of myocardial infarction, arterial thrombotic events, heart failure,&#xD;
             uncontrolled angina, severe uncontrolled ventricular arrhythmia&#xD;
&#xD;
          -  Received wide-field external beam radiation therapy within 4 weeks&#xD;
&#xD;
          -  Moderate to severe neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. George Private Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Liaw</last_name>
      <phone>+61 2 9598 5416</phone>
      <email>liawt@ramsayhealth.com.au</email>
    </contact>
    <investigator>
      <last_name>Paul De Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney South West Private Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeneen Attaullah</last_name>
      <phone>+61 2 8738 9156</phone>
      <email>Jeneen.Attaullah@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Adam Cooper, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Oncology Clinical Research</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meggan O'Riley</last_name>
      <phone>+61 8 8299 0706</phone>
      <email>meggan.oriley@socru.org.au</email>
    </contact>
    <investigator>
      <last_name>Sina VatanDoust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

